13 September 2018
A new visiongain report forecasts that the worldwide stem cell technological and applications market will generate revenues of $15.8bn in 2019. That forecast and others appear in Stem Cell Technologies and Applications Market Report 2016-2026: Hype vs Reality for That Transformative Technology with Vast R&D Pipeline and Expanding Use of HSCT and Cord Blood Banking, published in November 2015. Visiongain is a business information publisher and consultancy in London, UK.
Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Stem cells have been seen for many years as an upcoming and potentially transformative technology. In 2015, the market has yet to realise its great potential, but stem cell technologies remain on the cusp of significant market expansion. Factors such as the increasing use of hematopoietic stem cell transplantation (HSCT), the launch of current pipeline therapies and the expanding use of cord blood banking services and stem cell-based assays will stimulate this market over the next ten years.
“However the industry has many barriers to overcome. Current reimbursement and regulatory systems will need to be updated to adapt to the unique challenges posed by these non-traditional therapies. In addition, companies will have to attract the attention of Big Pharma, which sometimes remains wary of this exciting but potentially risky field.”
Visiongain’s updated analysis gives revenue forecasting to 2026 for the overall stem cell technologies and applications market. It also shows revenue predictions from 2015 to 2026 for the following five submarkets:
• Cancer treatment (oncology)
• Cardiovascular therapy
• CNS uses
• Other therapies
• Non-therapeutic applications.
The report also provides revenue forecasts to 2026 for six stem cell therapies:
• MSC-100-IV (Mesoblast)
• Hearticellgram-AMI (Pharmicell)
• CardioRel (Reliance Life Sciences)
• Osteocel Plus (NuVasive)
• Trinity Evolution and Elite (Orthofix)
• CARTISTEM (MEDIPOST).
That investigation shows interviews with the Human Stem Cells Institute (HSCI), Apceth, MEDIPOST, Harvard Stem Cells Institute and the Stem Cell Program at Boston’s Children’s Hospital. It also discusses research and development, reviewing the most promising advances. The study also discusses leading companies, assessing their activities and potentials.
Stem Cell Technologies and Applications Market Report 2016-2026 adds to visiongain’s analysis on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.